Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.
about
Nonpharmacological Treatments for ADHD: A Meta-Analytic ReviewADHD medications and risk of serious cardiovascular events in young and middle-aged adults.Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adultsAmphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adultsEfficacy of Psychostimulant Drugs for Cocaine DependenceAmfetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adultsImmediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsProfile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorderEfficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a reviewEfficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsBupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trialsSafety of stimulant treatment in attention deficit hyperactivity disorder: Part I.Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.Chronic D-amphetamine administered from childhood to adulthood dose-dependently increases the survival of new neurons in the hippocampus of male C57BL/6J mice.Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients.Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.Methylphenidate increases cigarette smoking in participants with ADHD.Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidateFactors associated with response to methylphenidate in advanced cancer patients.Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomiseAssessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative reviewLife impairments in adults with medication-treated ADHD.Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.Exploring the relationship among ADHD, stimulants, and substance abuse.Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses.Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.Developments and challenges in the diagnosis and treatment of ADHD.Addressing the lack of studies in attention-deficit/hyperactivity disorder in adults.Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.Evaluation of embedded malingering indices in a non-litigating clinical sample using control, clinical, and derived groups.Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.Use of Cognitive Behavioral Therapy and Token Economy to Alleviate Dysfunctional Behavior in Children with Attention-Deficit Hyperactivity Disorder.
P2860
Q22241802-C3B3F1F1-FD7A-4DC7-8F97-DD9C083B0550Q22253017-7452B301-74BD-490E-A843-F31BC4CC70AEQ24234795-F820FB1C-38A0-4933-A049-F006ABB09DCBQ24236404-6D36B7C0-F1EE-4DDF-A7C5-1F5965532F65Q24239994-60D96A00-9EC8-47B3-B8D7-3DB6FEE44445Q24241930-F0EDCAEB-A461-42EA-AC67-6969D58A5DF6Q26471999-9129732C-D4EF-4EAF-9DC7-69CB0282C552Q27692647-04FDE0EC-AB85-4378-B83C-3C55C4C26F59Q28068166-BE14E311-F1C0-4772-85E1-4D90A6C5E1E1Q28246506-9DA22952-4A5F-4629-BA27-6C4594DF5997Q28255609-93DCC928-705D-430E-92AA-7AC2741A5E67Q30449130-5FFD399D-E5AB-4EF3-9503-2DAE02D60414Q30451303-A31D7F15-978F-46C2-AF95-6E691652CD6BQ34313538-E7A869A4-9FEA-4BE0-A743-CF57F8516C38Q34475309-E044C198-7C47-4641-92C6-DF715324C2A0Q34497314-3CF76997-59FB-4F33-BFDD-FFD9E72D6263Q35001357-1702367F-DEAF-40E7-9516-01655BEAE248Q35293009-231C70CF-8590-4797-B38A-5F465C640963Q35579008-08FACB87-5812-47FC-9D9B-DF4EF509054DQ35584459-16DB0EF0-5431-4364-A119-FBB9CFA075EBQ36364178-D0EDDA0C-A2A9-4A30-9AA3-5EA5051B0E68Q36755295-A8D2D31D-7687-40CF-B6F2-A40A622BCEACQ36840424-2124BFB6-526A-4958-848E-382CD0F73219Q37318744-82DFC5D8-2040-4098-B25A-06612572405FQ37378254-C7FD8E4F-C1B1-4C3E-9203-9E00437A6AFAQ37598192-4C4799CE-4308-4919-AF61-7B8BF3ECCE2CQ37709983-5E068CD5-C6A8-4827-937D-203D443784B3Q37722786-3146BA25-C69B-44B2-BA22-A36425CB46A1Q38029373-BE0C80F2-743B-4A05-9870-91DC8988B067Q38043921-EB8EF0CC-8F90-4D66-9FA5-BAAD0E6B8FBBQ38060572-C8F3B90A-8BA6-493D-B73B-A70BA723C6F8Q38112253-BC4C6AF3-AA11-4ACF-9F76-26A062A67988Q38118231-A168922B-8385-439C-87BB-E0B2F5B62E9AQ38154181-53BBDA80-DA78-4C5B-8763-3AC0FB864920Q38205020-00C57BC4-6B79-4304-AC33-8D0C9620F1B4Q38241724-09D76F36-A463-4C41-B093-15810D3AAD72Q38407173-964B34B8-048D-487C-8082-C3EDA0565507Q39040595-E7FB0208-7F77-4D40-BDCA-CC66751D69D3Q41495299-F10FAF9C-1ADF-46E8-B197-3657418707D3Q41820491-8358DD80-11DF-4637-9656-F4343FE0F3B8
P2860
Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Comparative benefits and harms ...... rect comparison meta-analysis.
@ast
Comparative benefits and harms ...... rect comparison meta-analysis.
@en
Comparative benefits and harms ...... rect comparison meta-analysis.
@nl
type
label
Comparative benefits and harms ...... rect comparison meta-analysis.
@ast
Comparative benefits and harms ...... rect comparison meta-analysis.
@en
Comparative benefits and harms ...... rect comparison meta-analysis.
@nl
prefLabel
Comparative benefits and harms ...... rect comparison meta-analysis.
@ast
Comparative benefits and harms ...... rect comparison meta-analysis.
@en
Comparative benefits and harms ...... rect comparison meta-analysis.
@nl
P2093
P2860
P921
P1433
P1476
Comparative benefits and harms ...... rect comparison meta-analysis.
@en
P2093
Kim Peterson
Marian S McDonagh
Rongwei Fu
P2860
P2888
P356
10.1007/S00213-007-0996-4
P577
2007-11-17T00:00:00Z
P6179
1013579674